Pharma Capacity to Produce Cytotoxic Injectable Drugs Constricts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capacity to Produce Cytotoxic Injectable Drugs Constricts

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 7

The capacity of pharmaceutical contract manufacturing organizations (CMOs) to produce cytotoxic injectable drugs during the next five years will be tight, according to a new in-depth special report from PharmSource.

The report, The Demand and Supply for Contract Manufacturing of Cytotoxic Injectable Drugs Through 2019, presents detailed research and insight into the CMO industry’s ability to meet projected demand.

In developing the report, PharmSource’s researchers investigated quantitative factors such as FDA submissions and approvals, CMO closures and expansions, and injectable drugs currently in pipeline, including antibody drug conjugates (ADCs).

The researchers found that as an industry, CMOs have lost considerable capacity to manufacture cytotoxic injectable drugs. Indeed, although 21 CMOs claim they can produce cytotoxic injectable drugs, only five actually have the capability, track record, and market focus to be considered seriously for manufacturing high-value products like ADCs, said Jim Miller, president of PharmSource.

Given the current environment, report concluded that CMOs should be able to maintain pricing power and perhaps even force drug sponsors to commit to projects sooner than they’d like to in order to ensure necessary space, he said.

“The information we uncover in our latest report should prompt bio/pharmaceutical companies to reconsider their sourcing strategies and assess the adequacy of the CMO industry to manufacture products in pipeline,” he said. “It also should help CMOs make strategic investment decisions when it comes to producing cytotoxic injectable drugs.”

Source: PharmSource

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here